Identification by high-throughput sequencing of HPV variants and quasispecies that are untypeable by linear reverse blotting assay in cervical specimens.
Base Sequence
Cervix Uteri
/ virology
DNA, Viral
Female
Genetic Variation
Genotype
High-Throughput Nucleotide Sequencing
Humans
Molecular Typing
Papillomaviridae
/ classification
Papillomavirus Infections
/ complications
Phylogeny
Quasispecies
/ genetics
Sequence Analysis, DNA
Uterine Cervical Neoplasms
/ diagnosis
Genotyping
High-throughput sequencing
Human papillomavirus
Quasispecies
Variants
Journal
Papillomavirus research (Amsterdam, Netherlands)
ISSN: 2405-8521
Titre abrégé: Papillomavirus Res
Pays: Netherlands
ID NLM: 101662552
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
26
01
2019
revised:
11
05
2019
accepted:
03
06
2019
pubmed:
10
7
2019
medline:
28
4
2020
entrez:
9
7
2019
Statut:
ppublish
Résumé
The linear reverse blotting assays are valid methods for accurate human papillomavirus (HPV) typing required to manage women at risk of developing cervical cancer. However, some samples showed a positive signal in HPV lines but failed to display a positive signal in subsequent typing lines (designated as HPV-X), which indicate that certain types were not available on the respective typing blots. The aim of this study is to elucidate the types or variants of HPV through the high-throughput sequencing (HTS) of 54 ASCUS cervical samples in which the viruses remained untypeable with INNO LiPA HPV
Identifiants
pubmed: 31283993
pii: S2405-8521(19)30012-6
doi: 10.1016/j.pvr.2019.100169
pmc: PMC6620621
pii:
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100169Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Références
J Clin Microbiol. 2008 Oct;46(10):3215-21
pubmed: 18685007
Virol J. 2017 Jun 13;14(1):112
pubmed: 28610586
J Infect Dis. 2018 Aug 24;218(7):1027-1036
pubmed: 29788374
Bioinformatics. 2007 Nov 1;23(21):2947-8
pubmed: 17846036
Diagn Pathol. 2019 Apr 22;14(1):31
pubmed: 31010421
J Clin Microbiol. 2010 Jan;48(1):143-9
pubmed: 19864475
J Virol. 2005 Jun;79(11):6741-50
pubmed: 15890912
Cancer Sci. 2011 Jun;102(6):1223-7
pubmed: 21388488
Clin Microbiol Infect. 2018 Jan;24(1):29-36
pubmed: 28559000
PLoS One. 2014 Jan 20;9(1):e86835
pubmed: 24466262
J Pathol. 2012 Dec;228(4):534-43
pubmed: 22711526
PLoS One. 2016 Apr 28;11(4):e0154977
pubmed: 27123932
J Clin Virol. 2016 Mar;76 Suppl 1:S3-S13
pubmed: 26601820
BMC Clin Pathol. 2005 Nov 16;5:10
pubmed: 16288661
Virol J. 2015 Oct 06;12:161
pubmed: 26444975
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
J Gen Virol. 2018 Aug;99(8):989-990
pubmed: 29927370
Virology. 2013 May 25;440(1):1-7
pubmed: 23522725
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
J Clin Microbiol. 1999 Aug;37(8):2508-17
pubmed: 10405393
PLoS One. 2013 Nov 13;8(11):e80583
pubmed: 24236186
Virology. 2015 Feb;476:341-344
pubmed: 25577151
Vaccine. 2012 Nov 20;30 Suppl 5:F100-6
pubmed: 23199952
Int J Cancer. 2013 Feb 1;132(3):E139-48
pubmed: 22961598
J Virol. 2017 Sep 12;91(19):
pubmed: 28701400
Acta Cytol. 2011;55(4):341-3
pubmed: 21791903
Int J Mol Sci. 2018 Sep 11;19(9):null
pubmed: 30208597
Viruses. 2016 Jan 25;8(2):null
pubmed: 26821041
J Virol. 2018 May 29;92(12):
pubmed: 29593040
Virology. 2013 Oct;445(1-2):232-43
pubmed: 23998342
Diagn Cytopathol. 2012 Apr;40(4):367-73
pubmed: 21472869
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Am J Pathol. 1998 Dec;153(6):1731-9
pubmed: 9846964
J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62
pubmed: 9049358
J Virol Methods. 2006 Aug;135(2):181-5
pubmed: 16675035
J Virol Methods. 2015 Apr;215-216:22-9
pubmed: 25698462
J Clin Microbiol. 2011 May;49(5):1907-12
pubmed: 21068278
Virol J. 2012 Aug 16;9:164
pubmed: 22897914